Fujifilm's Diosynth Biothechnologies U.S.A. Inc. (FDBU) will acquire Kalon Biotherapeutics LLC in a deal that was finalized on Monday.
Kalon, which was founded in 2011 by the Texas A&M University System, is a biopharmaceutical contract manufacturing organization specializing in vaccine development. It is particularly known for utilizing mammalian cell cultures in creating vaccines.
As part of the acquisition agreement, FDBU initially will own 49 percent of interest shares and will be able to appoint a majority of Kalon's board members. It can acquire more shares of the company as certain milestones are reached.
Kalon is a key subcontractor to one of the Centers for Innovation In Advanced Development and Manufacturing. Funded by the U.S. Department of Health and Human Services, the centers are charged with developing medical countermeasures to such public health risks as bioterrorism and influenza at pandemic levels.